Congenital Heart Disease
Introduction
Congenital heart disease (CHD) refers to a range of structural abnormalities of the heart or great vessels that are present at birth. It is the most common type of birth defect, affecting millions of individuals worldwide and representing a significant global health challenge. These conditions vary widely in severity and complexity, from minor defects that may resolve spontaneously or require minimal intervention, to severe, life-threatening anomalies necessitating complex medical management and multiple surgical procedures throughout an individual's life.
Biological Basis
The development of CHD stems from errors during the intricate process of cardiac formation in the fetal stage. While some cases can be linked to specific environmental exposures or syndromic genetic disorders, many are considered multifactorial, arising from a complex interplay between genetic predispositions and environmental influences. Advances in genetic research, particularly through genome-wide association studies (GWAS), are instrumental in identifying specific genetic variants, such as single nucleotide polymorphisms (SNPs), that contribute to the risk and etiology of various heart conditions. [1] For example, genes like _RYR2_ have been implicated in conditions such as arrhythmogenic right ventricular dysplasia/cardiomyopathy [2] illustrating the critical role of genetics in cardiac health and disease.
Clinical Relevance
The clinical impact of CHD is profound, with manifestations ranging from asymptomatic conditions to severe functional impairments that can lead to heart failure, pulmonary hypertension, and other complications. Early and accurate diagnosis, often through prenatal screening or postnatal evaluation, is crucial for timely intervention. Medical management, including medications and interventional cardiology procedures, alongside surgical repair, are cornerstones of treatment aimed at correcting defects, improving heart function, and enhancing the long-term quality of life for affected individuals.
Social Importance
The burden of CHD extends beyond the individual, significantly impacting families, caregivers, and healthcare systems globally. The chronic nature of many CHDs often requires lifelong follow-up and specialized care, posing substantial emotional and financial challenges. Ongoing research into the genetic and environmental factors contributing to CHD is vital. By identifying specific genetic markers and understanding the underlying biological mechanisms, researchers aim to develop improved diagnostic tools, more targeted therapies, and ultimately, effective preventative strategies to reduce the incidence and impact of congenital heart disease on society.
Methodological and Statistical Power
Genetic studies of complex diseases, including congenital heart disease, often face significant methodological and statistical constraints that can impact the interpretation of findings. Achieving adequate statistical power for genome-wide association studies (GWAS) frequently necessitates very large sample sizes, as many common genetic variants contributing to complex traits exert only modest effects. [3] Studies with more modest sample sizes may therefore have limited power to detect associations, especially for variants with smaller effect sizes, potentially leading to false negative results or an inflation of effect-size estimates in the initial discovery phases. [4] Furthermore, the extensive number of hypotheses tested in GWAS requires stringent statistical correction, which, while reducing type I errors, can also mask true associations of moderate effect or lead to a conservative approach that increases false negative rates. [3]
Replication efforts are crucial for validating initial findings, but they too require comparably large sample sizes to confirm associations, especially given the potential for effect-size inflation in discovery cohorts. [5] A single failed replication attempt, or a set of underpowered replication studies, may not definitively rule out a true association. [6] Additionally, the genomic coverage of early GWAS platforms, often utilizing 100K single nucleotide polymorphism (SNP) arrays, may be insufficient to fully capture all relevant genetic variation within gene regions, suggesting that denser arrays or fine-mapping approaches are necessary for comprehensive assessment [7] Technical challenges such as the infallible detection of incorrect genotype calls also introduce a need for careful quality control, balancing stringency to avoid spurious findings with leniency to prevent discarding true signals. [5]
Phenotypic Definition and Scope
The accurate and consistent definition of complex phenotypes like congenital heart disease is critical but can be challenging, influencing the reproducibility and interpretation of genetic associations. Many complex diseases are clinically defined, which can introduce heterogeneity in the phenotype across different cohorts and ascertainment methods. [8] While some studies achieve high precision in quantitative measurements, such as those for electrocardiographic or subclinical atherosclerosis traits, the inherent complexity and varied presentations of congenital heart disease can make precise and universally consistent phenotyping difficult [3] The scope of traits examined in a single study might also be limited, potentially overlooking other relevant aspects of the disease or its progression that could be linked to identified genetic variants.
Generalizability and Population Structure
The generalizability of genetic findings for congenital heart disease can be constrained by the ancestry and demographic characteristics of the studied cohorts. Many GWAS are conducted predominantly in populations of European descent, which, while useful for discovery, limits the direct applicability of findings to diverse global populations [4] Differences in allele frequencies and linkage disequilibrium patterns across ancestries mean that genetic associations identified in one population may not translate directly to others. Furthermore, population structure or cryptic relatedness within study cohorts can confound genetic association analyses, leading to spurious findings if not meticulously controlled [9] Careful assessment and adjustment for population stratification, often using methods like principal component analysis, are therefore essential to ensure the robustness of observed associations [8]
Unaccounted Genetic and Environmental Factors
Despite advances in identifying genetic associations, a significant portion of the heritability for complex diseases like congenital heart disease often remains unexplained by common genetic variants identified through GWAS, a phenomenon known as "missing heritability." This gap suggests that other genetic factors, such as rare variants, structural variations, or epigenetic modifications, which are not typically captured by standard GWAS arrays, may contribute substantially to disease risk. Moreover, the interplay between genetic predispositions and environmental factors, or gene-environment interactions, represents a critical layer of complexity that is often not fully addressed in genetic association studies. Understanding these interactions is vital, as environmental exposures during critical developmental windows can profoundly influence the manifestation of congenital heart disease, yet current study designs may not adequately capture these complex relationships, leaving significant knowledge gaps in the complete etiology of the disease.
Variants
Genetic variations play a crucial role in the development and function of the cardiovascular system, with certain changes potentially influencing the risk and presentation of congenital heart disease (CHD). These variants, located within or near genes, can alter protein function, gene expression, or cellular pathways essential for proper heart formation and maintenance. Understanding their roles offers insights into the complex genetic architecture of CHD.
Several genes involved in fundamental cellular processes are associated with variants that could impact cardiac development. GOSR2 (Golgi SNAP Receptor Complex Member 2) is crucial for the transport of vesicles within cells, a process essential for delivering proteins and lipids to their correct destinations. Disruptions by variants like rs16941382 could impair cellular organization and function, which is particularly vital during the rapid cell division and differentiation stages of embryonic heart development. YTHDC2 (YTH Domain Containing 2) plays a role in regulating messenger RNA (mRNA) processing and stability, influencing which proteins are made and in what quantities. A variant such as rs185531658, which is also associated with KCNN2, might alter this intricate control, potentially affecting the precise gene expression required for proper heart formation. [10] Similarly, FBXO33 (F-box protein 33) is part of a complex that tags proteins for degradation, a critical mechanism for controlling protein levels and cellular pathways. LINC02315 is a long intergenic non-coding RNA, often involved in regulating gene expression. A variant like rs11768641, associated with both FBXO33 and LINC02315, could lead to either an accumulation or deficiency of specific proteins or alter regulatory RNA functions, potentially disrupting signaling pathways necessary for cardiac morphogenesis and contributing to congenital heart disease. [2]
Other variants are found in genes with direct or indirect impacts on cardiac function and structure. The KCNN2 gene, also linked to rs185531658, encodes a potassium channel that is important for regulating the electrical activity of heart cells, influencing heart rate and rhythm. Alterations due to this variant could predispose individuals to arrhythmias or structural defects, common features in congenital heart disease. [3] SLC44A2 (Solute Carrier Family 44 Member 2) is involved in transporting choline, a nutrient vital for cell membrane synthesis and neurotransmitter production. A variant like rs2360743 might impair these fundamental cellular processes, indirectly affecting the growth and integrity of cardiac tissues during development. Furthermore, LRP1B (LDL Receptor Related Protein 1B) is a large receptor involved in cell signaling, growth, and the removal of various substances from circulation, playing a role in tissue remodeling. A variant such as rs11895588 could disrupt these regulatory functions, potentially impacting the complex architectural development of the heart and its vessels. [7]
Some variants are found in genes or regions with known or suspected regulatory functions, or direct disease associations. OFCC1 (OculoFacioCardioDental Syndrome 1) is a gene whose mutations are known to cause Oculo-facio-cardio-dental syndrome, a condition characterized by abnormalities including congenital heart defects, highlighting its direct relevance to cardiac development. A variant like rs56409046, associated with the HULC - OFCC1 region, could therefore directly contribute to the risk of such structural heart anomalies. Non-coding RNAs such as STX18-AS1 (Syntaxin 18 Antisense RNA 1) and HULC (Highly Upregulated in Liver Cancer) act as regulators of gene expression. Variants like rs870142 in STX18-AS1 or rs56409046 in HULC could alter the expression of critical genes involved in cardiac development, potentially leading to malformations. [8] Other genes like RPRML and pseudogenes such as LRRC37A17P, HMGB1P47, and RNA5SP182 are less directly characterized but may play subtle regulatory roles or be in proximity to functional genes. Variants like rs2316327 and rs12186641 within these regions or genes could indirectly influence developmental pathways through their impact on nearby gene regulation or chromatin structure, contributing to the complex genetic landscape of congenital heart disease. [11] Lastly, DRD3 (Dopamine Receptor D3) is primarily known for its role in the brain, but dopamine signaling also influences cardiovascular regulation. A variant such as rs66678247, associated with DRD3 and ATOSBP1, could impact these regulatory pathways, potentially affecting heart function or development.
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs16941382 | GOSR2 | congenital heart disease |
| rs2316327 | RPRML - LRRC37A17P | congenital heart disease |
| rs185531658 | YTHDC2 - KCNN2 | congenital heart disease heart septal defect |
| rs870142 | STX18-AS1 | congenital heart disease heart septal defect |
| rs2360743 | SLC44A2 | congenital heart disease |
| rs11895588 | LRP1B | congenital heart disease |
| rs66678247 | DRD3 - ATOSBP1 | congenital heart disease |
| rs12186641 | HMGB1P47 - RNA5SP182 | congenital heart disease |
| rs56409046 | HULC - OFCC1 | congenital heart disease |
| rs1176869 | FBXO33 - LINC02315 | congenital heart disease |
Biological Background
Congenital heart disease encompasses a range of structural and functional abnormalities of the heart that are present at birth, often stemming from complex interactions between genetic predispositions and environmental factors during fetal development. While the term broadly covers conditions evident from birth, the underlying biological mechanisms involve intricate molecular pathways, genetic regulations, and cellular processes that dictate cardiac formation and function throughout life. Understanding these fundamental biological aspects, from the gene level to organ systems, is crucial for unraveling the origins and progression of various heart conditions.
Genetic Foundations and Regulatory Pathways
The development and function of the heart are orchestrated by a complex interplay of genes, many of which encode critical transcription factors and structural proteins. For instance, mutations in the MEF2A gene have been identified in inherited disorders characterized by features of coronary artery disease, highlighting its role in cardiovascular health. [2] Similarly, mutations within the MYH7 gene, which encodes cardiac muscle beta-myosin heavy chain 7, are known to cause inherited forms of cardiomyopathy, demonstrating how disruptions in structural components can lead to heart muscle disease. [8] Another key player is ZFHX3 (also known as ATBF1), a large enhancer-binding transcription factor that is polymorphic and interacts with various proteins, including PIAS3 (protein inhibitor of activated STAT). [8] These interactions form regulatory networks that control gene expression, influencing cell differentiation, growth, and the proper formation of cardiac tissues.
Beyond individual gene mutations, variations in regulatory elements and epigenetic modifications also contribute to the genetic landscape of heart disease. The transcription factor ZFHX3, through its interaction with PIAS3, inhibits STAT3 (signal transducer and activator of transcription-3), a protein activated by the pro-inflammatory cytokine IL6 (interleukin 6). [8] This regulatory axis illustrates how gene expression patterns are fine-tuned, impacting cellular responses to inflammation and stress. Additionally, the gene CSMD1 (CUB and Sushi multiple domains 1) is functionally related to CaM kinase II via histone deacetylase 4 (HDAC4), suggesting a role for chromatin remodeling and signal transduction in cardiac biology. [8] Such intricate regulatory networks, involving transcription factors, signaling molecules, and epigenetic modifiers, underscore the sophisticated genetic control over heart development and disease susceptibility.
Molecular Signaling and Cellular Function
Cellular functions within the heart are largely governed by intricate molecular signaling pathways that ensure proper development, maintenance, and response to physiological changes. For example, the protein LGALS2 has been found to regulate lymphotoxin-alpha secretion in vitro, and variations in this gene confer a risk of myocardial infarction, highlighting its role in immune and inflammatory signaling relevant to cardiac health. [2] The activation of STAT3 by IL6, a pro-inflammatory cytokine, exemplifies how external signals trigger intracellular pathways that modulate cellular processes, including immune responses and acute phase reactions. [8] These signaling cascades are crucial for maintaining cellular homeostasis and responding to stressors that can lead to disease.
Disruptions in these molecular pathways can lead to significant cellular dysfunction, impacting the structural integrity and electrical activity of the heart. The functional relationship between CSMD1 and CaM kinase II, mediated by HDAC4, points to the involvement of calcium signaling and protein modification in cellular regulation. [8] Furthermore, the gene NOS1AP has been associated with variations in the QT interval on an electrocardiogram, indicating its involvement in the complex cellular mechanisms that control cardiac electrical conduction. [7] These examples demonstrate how specific biomolecules and their associated pathways are critical for healthy cardiac cellular function, and their dysregulation can predispose individuals to various heart conditions.
Developmental Pathophysiology and Organ-Level Effects
The healthy development of the heart is a highly coordinated process, and deviations can lead to pathophysiological processes manifesting at the tissue and organ level. Cardiac remodeling, a process involving changes in heart size, shape, and function, can be influenced by genetic factors and represents a key disease mechanism in various heart conditions. [12] Similarly, disruptions in the complex electrical signaling of the heart can lead to cardiac arrhythmias, which also have a genetic basis. [13] These developmental and homeostatic disruptions can lead to organ-specific effects, such as the inherited forms of cardiomyopathy caused by mutations in MYH7, which directly impact the heart muscle's ability to pump blood effectively. [8]
Beyond the heart muscle itself, other cardiovascular tissues are also affected. Endothelial function, critical for maintaining vascular health and blood flow, can be impaired in conditions like Kawasaki disease, contributing to cardiovascular damage. [8] The systemic consequences of such disruptions can be far-reaching, affecting overall cardiovascular performance. For instance, variations associated with coronary artery disease, which can have an inherited basis, affect the arteries supplying the heart, leading to reduced blood flow and potential myocardial infarction . [2], [14] These examples highlight how molecular and cellular dysfunctions translate into significant structural and functional problems at the organ level, impacting the heart's ability to maintain systemic circulation.
Immune-Mediated Responses and Systemic Consequences
The immune system plays a significant role in the pathophysiology of certain heart conditions, with systemic consequences impacting cardiovascular health. Kawasaki disease, for example, is a condition where more than one infectious trigger can lead to cardiovascular damage in genetically susceptible individuals. [8] This disease is characterized by early innate immune reactivity, high fever, and an acute phase response, involving increased levels of C-reactive protein (CRP), complement factors, and fibrinogen in the blood, alongside altered cellular markers. [8] The activation of complement pathways is a known feature of Kawasaki syndrome, demonstrating a direct link between immune activation and disease pathology. [8]
The systemic inflammatory response observed in conditions like Kawasaki disease can have profound effects on the cardiovascular system. The pro-inflammatory cytokine IL6 activates STAT3, a signal transducer, which contributes to this acute phase response. [8] Such widespread inflammation and immune activation can lead to damage in various tissues, including the heart and blood vessels, ultimately contributing to cardiovascular complications. The interplay between genetic susceptibility and immune responses underscores how the body's protective mechanisms can, under certain circumstances, contribute to the development and progression of heart conditions with systemic ramifications.
Genetic and Transcriptional Regulation in Cardiac Development
Congenital heart disease often stems from dysregulation of genes and transcription factors critical for cardiac formation and function. For instance, ZFHX3 (also known as ATBF1), a large enhancer-binding transcription factor, plays a role in gene regulation and is known to be polymorphic. [8] Mutations in genes such as MEF2A have been linked to inherited disorders presenting with features of coronary artery disease, highlighting the importance of specific genetic blueprints for cardiovascular health. [15] Furthermore, the genetic basis for cardiac remodeling, a process that can lead to structural and functional abnormalities, is an area of ongoing research. [12]
Regulatory mechanisms extend to post-translational modifications and allosteric control, which fine-tune gene expression. The TGF-beta signaling pathway, for example, utilizes Smad3 proteins, whose allosteric changes link TGF-beta receptor kinase activation directly to the control of target gene transcription. [16] This intricate control ensures proper cellular responses during development. Moreover, the gene CSMD1 is functionally related to CaM Kinase II through HDAC4 (histone deacetylase 4), which suggests an epigenetic regulatory layer where histone modification influences gene expression relevant to cardiac cells. [8]
Signaling Cascades and Cellular Communication
Intricate signaling cascades are fundamental to the development and maintenance of the heart. CAMK2D (calcium/calmodulin-dependent protein kinase II delta), a ubiquitously expressed calcium-sensitive serine/threonine kinase, is central to a putative gene network associated with cardiovascular pathology. [8] This isoform is predominant in cardiomyocytes and vascular endothelial cells, where it mediates nitric oxide (NO) production by endothelial synthase (NOS3) in response to intracellular calcium fluctuations, which in turn influences local vasodilation. [8] Dysregulation of this pathway, including decreased NOS3 activity and impaired endothelial function, can contribute to cardiovascular issues. [17]
Another critical signaling pathway involves STAT3 (signal transducer and activator of transcription-3), which is activated by pro-inflammatory cytokines such as IL6 (interleukin 6). [8] This activation plays a role in early innate immune reactivity, characterized by acute phase responses including increased levels of CRP (C-reactive protein), complement factors, and fibrinogen. [8] The activity of STAT3 is inhibited by PIAS3 (protein inhibitor of activated STAT), which interacts with transcription factors like ZFHX3, illustrating complex feedback loops that modulate inflammatory responses and cellular fate. [8]
Network Interactions and Cardiovascular Dysregulation
Congenital heart disease can arise from complex network interactions and pathway crosstalk, where the malfunction of one component can have cascading effects across multiple systems. A closely related gene network, identified in studies of cardiovascular damage, suggests mechanisms by which various triggers can lead to dysregulated inflammation, apoptosis, and subsequent cardiovascular pathology. [8] For instance, the transcription factor ZFHX3 interacts directly with MYH7 (myosin, heavy chain 7, cardiac muscle, beta), a gene in which mutations are known to cause inherited forms of cardiomyopathy. [8]
Beyond direct protein-protein interactions, systems-level integration involves the interplay of different signaling pathways that are crucial for cardiac development. An example of such crosstalk, though studied in the context of Hirschsprung's disease, highlights that interactions between the RET and EDNRB pathways are critical for proper development, and their dysregulation can lead to congenital defects, including cardiac anomalies. [18] The identification of specific gene variants, such as in LGALS2 conferring risk of myocardial infarction, or in ECE-1 (endothelin-converting enzyme 1) associated with cardiac defects, further underscores the importance of these interconnected genetic and molecular networks in cardiovascular health. [15]
Inflammatory and Immune-Mediated Mechanisms
Inflammation and immune responses are deeply integrated with cardiovascular health, and their dysregulation can contribute to congenital heart conditions. The activation of STAT3 by IL6 initiates a significant pro-inflammatory response, essential for early innate immunity but potentially harmful if uncontrolled. [8] This pathway leads to the acute phase response, marked by elevated CRP and complement factors, which are indicative of systemic inflammation. [8]
The intricate balance of immune regulation is also exemplified by proteins like CSMD1, identified as a novel multiple-domain complement-regulatory protein. [19] Its functional link to CaM Kinase II via HDAC4 suggests a regulatory axis where immune responses and calcium signaling pathways converge, potentially impacting cardiovascular cell function and integrity. [8] Dysregulation within these inflammatory and immune pathways, whether due to genetic susceptibility or environmental triggers, can contribute to the development of cardiovascular pathology.
Frequently Asked Questions About Congenital Heart Disease
These questions address the most important and specific aspects of congenital heart disease based on current genetic research.
1. If I have CHD, will my kids get it too?
It depends. While congenital heart disease often has a genetic component, many cases are considered multifactorial, meaning they arise from a complex interplay between genetic predispositions and environmental influences. Your specific genetic variants can increase risk, but it's not always a direct inheritance pattern, so your children might have a higher risk, but it's not guaranteed.
2. My sibling has CHD, but I don't. Why?
This is common because CHD is complex. Even with shared genetic predispositions, the interplay with environmental factors can lead to different outcomes for siblings. The condition also varies widely in severity and presentation, so some individuals might have very mild, undetected forms, while others have more severe issues.
3. Can my lifestyle choices affect my child's heart development?
Yes, environmental influences can play a role in the development of congenital heart disease. While genetics are a major factor, some cases are linked to specific environmental exposures during fetal development. This combination of genetic predisposition and environmental factors makes it a multifactorial condition.
4. Is a genetic test useful if my family has heart issues?
Genetic research is actively identifying specific genetic variants that contribute to various heart conditions. For example, genes like _RYR2_ have been implicated in conditions such as arrhythmogenic right ventricular dysplasia/cardiomyopathy. While not all CHDs have a clear genetic marker identified yet, understanding your family's specific genetic predispositions can be valuable for risk assessment.
5. Can doctors tell if my baby has CHD before birth?
Yes, early and accurate diagnosis is crucial for congenital heart disease, and it often happens through prenatal screening. This allows for timely intervention and preparation for medical management, including medications or surgical repair, right after birth if needed.
6. Does my ethnic background change my risk for CHD?
Yes, it can. Many genetic studies have been conducted predominantly in populations of European descent. This means that genetic associations identified in one population may not translate directly to others due to differences in allele frequencies and linkage disequilibrium patterns across ancestries. Your specific ancestry can therefore influence your risk factors.
7. Why do some people with CHD live normal lives, but others struggle?
Congenital heart disease varies widely in its severity and complexity. Some defects are minor and may resolve spontaneously or require minimal intervention, allowing for a near-normal life. Others are severe, life-threatening anomalies that necessitate complex medical management, multiple surgeries, and can lead to significant functional impairments and lifelong challenges.
8. Does my CHD mean I'll have health problems later in life?
Often, yes. The chronic nature of many congenital heart diseases frequently requires lifelong follow-up and specialized care. Manifestations can range from asymptomatic conditions to severe functional impairments that can lead to complications like heart failure or pulmonary hypertension over time.
9. What causes my baby's heart defect? Was it something I did?
It's important to understand that congenital heart disease often arises from a complex interplay between genetic predispositions and environmental influences during fetal heart formation. While some cases can be linked to specific environmental exposures, it's rarely due to a single action or fault. Many factors, often beyond anyone's control, contribute to these conditions.
10. Can I still exercise normally with my CHD?
It depends on the specific nature and severity of your condition. While some individuals with CHD may experience severe functional impairments, leading to limitations, others might have minor defects that resolve or are well-managed. Medical management and surgical repair aim to improve heart function, but it's crucial to discuss appropriate activity levels with your doctor.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Lunetta, K. L., et al. "Genetic correlates of longevity and selected age-related phenotypes: a genome-wide association study in the Framingham Study." BMC Med Genet, 2007.
[2] Larson MG. et al. "Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes." BMC Med Genet, 2007.
[3] Newton-Cheh C. et al. "Genome-wide association study of electrocardiographic and heart rate variability traits: the Framingham Heart Study." BMC Med Genet, 2007.
[4] Barrett, Jeffrey C. et al. "Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease." Nat Genet, vol. 40, no. 8, 2008, pp. 955-962.
[5] Wellcome Trust Case Control Consortium. "Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls." Nature, vol. 447, no. 7145, 2007, pp. 661-678.
[6] Pillai, S. G. et al. "A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci." PLoS Genet, vol. 5, no. 3, 2009, e1000421.
[7] O'Donnell CJ. et al. "Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study." BMC Med Genet, 2007.
[8] Burgner D. et al. "A genome-wide association study identifies novel and functionally related susceptibility Loci for Kawasaki disease." PLoS Genet, 2009.
[9] Carrasquillo, M. M. et al. "Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease." Nat Genet, vol. 42, no. 3, 2010, pp. 199-201.
[10] Pankratz N. et al. "Genomewide association study for susceptibility genes contributing to familial Parkinson disease." Hum Genet, 2008.
[11] Erdmann J. et al. "New susceptibility locus for coronary artery disease on chromosome 3q22.3." Nat Genet, 2009.
[12] Ahmad, F., Seidman, J. G., and Seidman, C. E. "The genetic basis for cardiac remodeling." Annu Rev Genomics Hum Genet, vol. 6, 2005, pp. 185-216.
[13] Roberts, R. "Genomics and cardiac arrhythmias." J Am Coll Cardiol, vol. 47, 2006, pp. 9-21.
[14] Samani, N. J., et al. "Genomewide association analysis of coronary artery disease." N Engl J Med, 2007.
[15] Wang, L., et al. "Mutation of MEF2A in an inherited disorder with features of coronary artery disease." Science, 2003, 302:1578-1581.
[16] Qin, B.Y., et al. "Smad3 allostery links TGF-beta receptor kinase activation to transcriptional control." Genes Dev, 2002, 16:1950-63.
[17] Deng, Y.B., et al. "Impaired endothelial function in the brachial artery after Kawasaki disease and the effects of intravenous administration of vitamin C." Pediatr Infect Dis J, 2003, 22:34-39.
[18] Hofstra, R.M., et al. "A loss-of-function mutation in the endothelin-converting enzyme 1 (ECE-1) associated with Hirschsprung disease, cardiac defects, and autonomic dysfunction." Am J Hum Genet, 1999, 64:304-308.
[19] Kraus, D.M., et al. "CSMD1 is a novel multiple domain complement-regulatory protein highly expressed in the central nervous system and epithelial tissues." J Immunol, 2006, 176:4419-4430.